A clinical diagnostics intelligence platform company, MaxQ AI and NeuroLogica, a subsidiary of Samsung Electronics Co., Ltd., a leader in medical imaging technology, has announced earlier this week a distribution agreement to integrate MaxQ’s Artificial Intelligence software with Samsung NeuroLogica’s medical imaging hardware in the U.S. and European Union acute care marketplace.
As part of this agreement, Samsung NeuroLogica will be able to improve its offerings with MaxQ’s Accipio Ix, part of MaxQ’s unique Accipio INSIGHT™ intracranial hemorrhage platform that supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those victims, using adult non-contrast head Computed Tomography (CT) imaging.
SVP Commercial Operations for MaxQ AI, Chris Schnee said that following the recent FDA clearance and CE Mark approval of Accipio Ix, their company’s partnership with Samsung NeuroLogica will further accelerate the commercialization of MaxQ AI’s AI-powered solutions for the acute care market. Schnee further said that designed for seamless integration into CT and PACS systems, MaxQ AI’s platform joined with the unique mobile CT offering of Samsung Neurologica, will take critical life-saving decisions directly to patients in Mobile Stroke Units (MSU) and to the bedside of acute care hospital departments. Samsung NeuroLogica’s U.S. and E.U. sales teams will now provide Accipio Ix™ solution as an additional tool for its OmniTom® mobile 16-slice CT scanner, the world’s first medical device delivering high-quality non-contrast CT scans at the patients’ bedside with Omni-directional wheels. In addition, MaxQ’s AI solutions will be accessible for integration into Samsung NeuroLogica’s U.S. and E.U. MSU, a specialized ambulance or other emergency vehicles that are equipped with a CereTom® CT scanner. The mobile unit with analytical CT imaging capabilities is designed to enable the team onboard to quickly review whether a patient is having a stroke caused by hemorrhage.
Chief Operating Officer of NeuroLogica, David Webster said that they are privileged to join with MaxQ and their flagship product Accipio Ix. AI is an exciting development in healthcare, and through this joint effort, NeuroLogica will work to improve diagnostic accuracy and reduce time to treatment for stroke. Additionally, Webster pointed out that AI has the potential to revolutionize diagnostics, and this collaboration will bring that potential into the patient’s room through company’s point of care CT systems.